Options Wonderland

[3xBuBu]

Biotech New Bundle: ZIOPHARM, MannKind, VIVUS, Ariad Pharmaceuticals, Infinity Pharmaceuticals, Sarepta Therapeutics, Sequenom, Exelixis, Halozyme Therapeutics, InterMune
http://www.therem.org/biotech-new-bundle-ziopharm-mannkind-vivus-ariad-pharmaceuticals-infinity-pharmaceuticals-sarepta-therapeutics-sequenom-exelixis-halozyme-therapeutics-intermune/124239/#.UcDQvJz9z74

http://stockcharts.com/freecharts/candleglance.html?INFI,ZIOP,MNKD,ITMN,VVUS,ARIA,SRPT,SQNM,EXEL,HALO|B|C20,G14


http://stockcharts.com/freecharts/gallery.html?INFI








ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) traded 18.13% higher to close last trading session at $2.02 with no company news related to unusual activity, according to ZIOPHARM IR Spokesperson. The company is set to present on May 29 at Deutsche Bank Health Care Conference. The stock floated in a range of $1.71to $2.02 on volume of 2.55M shares as compared to average-daily volume of 885,669.00 shares. The recent closing price brought its year-to-date performance at -51.44%.

MannKind Corporation (NASDAQ:MNKD) traded 9.95% higher to close last trading session at $6.85, extending gains to new high after Seeking Alpha contributor George Rho speculated the biopharmaceutical company is a ripe takeover target. The stock floated in a range of $6.23 to $6.99 on volume of 20.00M shares as compared to average-daily volume of 6.10M shares. The recent closing price brought its year-to-date performance at 196.54%.

VIVUS, Inc. (NASDAQ:VVUS) traded 7.25% higher to close last trading session at $14.50 after saying that in response to Vivus’ recent expansions of the Board it has increased its slate of director nominees to nine, adding Alex Denner, Ph.D. The stock floated in a range of $13.12 to $15.04 on volume of 6.74M shares as compared to average-daily volume of 2.56 shares. The recent closing price brought its year-to-date performance at +8.05%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded 5.48% higher to close last trading session at $19.44, extending rally after its presentation at the UBS Global Healthcare Conference. The company is also set to present at Deutsche Bank dbAccess Health Care Conference on May 30 at 10:00AM EDT. The stock floated in a range of $17.76 to $20.00 on volume of 4.71M shares as compared to average-daily volume of 3.10M shares. The recent closing price brought its year-to-date performance at +1.36%.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded 5.36% higher to close last trading session at $24.36. The company is scheduled to present at Deutsche Bank’s 38th Annual Health Care Conference on May 29, 2013, at 4:15 p.m. ET in Boston, MA. The stock floated in a range of $22.42 to $24.83 on volume of 1.55M shares as compared to average-daily volume of 1.67M shares. The recent closing price brought its year-to-date performance at -30.04%.

Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 4.46% higher to close last trading session at $37.94, seemingly on news that Soros Fund Management increased its stake in Sarepta, according to Soros’s latest quarterly 13F filing. The stock floated in a range of $35.14 to $38.33 on volume of 1.29M shares as compared to average-daily volume of 1.93 shares. The recent closing price brought its year-to-date performance at 47.05%.

Sequenom, Inc. (NASDAQ:SQNM) traded 4.35% higher to close last trading session at $4.08 after a Seeking Alpha blog post suggested the stock has plenty of room to grow. The stock floated in a range of $3.86 to $4.10 on volume of 4.15M shares as compared to average-daily volume of 2.59M shares. The recent closing price brought its year-to-date performance at -13.38%.

Exelixis, Inc. (NASDAQ:EXEL) traded 4.15% higher to close last trading session at $4.77 after it filed SEC form 8-K revealing submission of matters to a Vote of Security Holders. The stock floated in a range of $4.51 to $4.78 on volume of 1.17M shares as compared to average-daily volume 1.63M shares. The recent closing price brought its year-to-date performance at 4.38%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded 3.91% higher to close last trading session at $7.45 after promotion of David A. Ramsay to chief financial officer. The stock floated in a range of $6.78 to $7.54 on volume of 1.53M shares as compared to average-daily volume of 1.36M shares. The recent closing price brought its year-to-date performance at 11.03%.

InterMune Inc (NASDAQ:ITMN) traded 3.75% higher to close last trading session at $9.96 with no clear reason. The stock floated in a range of $9.27 to $10.03 on volume of 1.13M shares as compared to average-daily volume of 1.45 shares. The recent closing price brought its year-to-date performance at 2.79%.